Using Polyanionic Heparin Mimetics for the treatment of COPD by Ip, MSM et al.
Title Using Polyanionic Heparin Mimetics for the treatment of COPD
Author(s) Wu, LK; Chan, CH; Tan, C; Mak, JCW; Lam, DCL; Ip, MSM; Shum,DKY
Citation
The 2014 Hong Kong Inter-University Biochemistry Postgraduate
Symposium, Hong Kong, 14 June 2014. In Program Booklet,
2014, p. 24, poster no. 23
Issued Date 2014
URL http://hdl.handle.net/10722/203853
Rights Creative Commons: Attribution 3.0 Hong Kong License
24 
 
Poster 
Number 
 
23 Using Polyanionic Heparin Mimetics for the treatment of COPD 
KLK Wu*, SCH Chan*, JCL Tan^, JCW Mak^, DCL Lam^, MSM Ip^, DKY Shum* 
Departments of Biochemistry* and Medicine^, LKS Faculty of Medicine, The University of Hong Kong, 
Sassoon Road, Hong Kong, China. 
 
COPD patients suffer from sustained inflammation leading to airway damage and deteriorating 
lung function caused by unopposed protease activity resulting from a1-antitrypsin resistant 
supramolecular complexes of neutrophil elastase and shed syndecan-1 in the airway. It was 
further shown that the action of the GAG digesting enzyme heparanase facilitates syndecan-1 
shedding. 
  
We hypothesize that the use of a polyanionic heparin mimetic would 1) displace neutrophil 
elastase from syndecan-1 rendering it susceptible to a1-antitrypsin inhibition and 2) inhibit 
heparanase activity in the airway. 
  
In vitro tests show that the heparin mimetic successfully displaced neutrophil elastase from 
high molecular weight supramolecular complexes with syndecan-1. The dissociated neutrophil 
elastase was then rapidly inhibited by endogenous a1-antitrypsin. A similar degree of complex 
dissociation and resultant neutrophil inhibition was also shown to be present in BA samples of 
COPD patients. We also demonstrate that the heparin mimetic was capable of reducing 
heparanase activity and heparanase-induced syndecan-1 shedding using an air-liquid interface 
model of the lung. 
 
To assess the feasibility of using the mimetic as a treatment for COPD, we treated cigarette 
smoke-induced COPD rats with an aerosol preparation of the mimetic. Preliminary results 
indicated that the number of neutrophils and neutrophil elastase amount in the lung was 
significantly decreased compared to rats treated with carrier alone. This suggests that our 
preparation can serve as a potential drug for the treatment of COPD. 
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Both Parp1 and Timeless have been implicated in DNA damage response, while there is no 
report that Parp1 could function together with Timeless. We have, for the first time, provided 
the evidence that Parp1 binds to Timeless both in vitro and in vivo. In addition, we present the 
crystal structure of Timeless in complex with Parp1, and demonstrate that Timeless-Parp1 
complex facilitates homologous recombination repair. 
 
 
 
 
 
 
 
 
 
 
 
 
